shot-button
Ganesh Chaturthi Ganesh Chaturthi
Home > News > India News > Article > Covaxin to be evaluated as Covid 19 vaccine candidate in US Bharat Biotech

Covaxin to be evaluated as Covid-19 vaccine candidate in US: Bharat Biotech

Updated on: 19 February,2022 07:58 PM IST  |  Hyderabad
ANI |

Earlier, the Ministry of Health and Family Welfare had informed that Covaxin has been granted approval for emergency use in 13 countries as of January 31, 2022

Covaxin to be evaluated as Covid-19 vaccine candidate in US: Bharat Biotech

Representative image

Hyderabad-based Bharat Biotech said its Covid-19 vaccine Covaxin will be evaluated as a vaccine candidate for the disease in the United States.


"Ocugen, Inc (NASDAQ: OCGN) announced that the US Food and Drug Administration (FDA) has lifted its clinical hold on the Company's Investigational New Drug application (IND) to evaluate the Covid-19 vaccine candidate, BBV152, known as Covaxin outside the United States. Ocugen, Inc is co-developing Bharat Biotech's Covaxin vaccine candidate for Covid-19 in USA and Canada," reads Bharat Biotech's statement.



Earlier, the Ministry of Health and Family Welfare had informed that Covaxin has been granted approval for emergency use in 13 countries as of January 31, 2022.


This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!

Register for FREE
to continue reading !

This is not a paywall.
However, your registration helps us understand your preferences better and enables us to provide insightful and credible journalism for all our readers.

Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK